Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...

Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...

RWJBarnabas Health appoints Steven Stylianos, MD as system director for pediatric surgery and surgeon-in-chief at Bristol-Myers Squibb Children's Hospital ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Keros and Takeda on Tuesday said the deal gives Takeda an exclusive license to further develop, manufacture and commercialize elritercept outside of mainland China, Hong Kong and Macau in exchange for ...

Bristol Myers Squibb became the latest large drugmaker to sue the federal government over a plan to change how it doles out ...

The outlay, plus up to $1.1 billion in milestones, has secured Takeda ex-China rights to a molecule that could compete with ...

Bristol Myers Squibb has enlisted three-year-old Massachusetts biotech AI Proteins to use its artificial-intelligence-driven ...

We recently published a list of 10 Stocks That Are Close To Becoming Dividend Aristocrats. In this article, we are going to ...

Founded in 2018, Insitro is part of a growing field of AI companies promising to accelerate drug discovery by using machine ...

Despite billions poured into research, new medicines still typically take a decade or more to develop.

Income investors are drawn to Aristocrats because these stocks have consistently increased their dividends for decades.